The Pan American Health Organization (PAHO) and the World Health Organization (WHO) have issued an epidemiological alert due to the increased circulation of the DENV-3 serotype in the Americas Region, which may raise the risk of outbreaks and severe cases. Countries are advised to prepare for a higher healthcare burden during the peak dengue season, focusing on early diagnosis and timely treatment.
Historic Increase in Cases in 2024
A total of 13,027,747 dengue cases were reported across 50 countries, including 6,906,396 confirmed cases, 22,684 severe dengue cases, and 8,186 deaths (case fatality rate: 0.063%).
Most Affected Countries in 2024
- Brazil: 10,232,872 cases
- Argentina: 581,559 cases
- Mexico: 558,846 cases
- Colombia: 320,982 cases
- Paraguay: 295,785 cases
2025 Data (Epidemiological Weeks 1–4)
A total of 238,659 dengue cases were reported across 23 countries. Six countries accounted for 98% of the cases:
- Brazil (87%)
- Colombia (5.6%)
- Nicaragua (2.5%)
- Peru (2.5%)
- Mexico (2.5%)
Additionally, 57,899 cases were confirmed by laboratory testing, with 263 severe dengue cases and 23 deaths (case fatality rate: 0.010%).
Circulation of All Four Dengue Serotypes
DENV-1, DENV-2, DENV-3, and DENV-4 have been simultaneously detected in Brazil, Costa Rica, El Salvador, Mexico, and Panama.
Risk Associated with the Increased Circulation of DENV-3
Historical Epidemiology
- In 1994, DENV-3 was reintroduced to the Americas after 16 years of absence.
- Between 2000–2007, it became one of the most frequently detected serotypes in the region, triggering major outbreaks in Brazil, Central America, and the Caribbean.
- Since 2023, several countries have documented the reemergence and spread of DENV-3, increasing the risk of severe cases.
Situation in 2024–2025
- Argentina: Circulation of a new DENV-3 genotype in Entre Ríos.
- Brazil: Reemergence of DENV-3 after several years of low circulation.
- Colombia: Severe cases reported in the Casanare region.
- Costa Rica: DENV-3 prevalence rose from 25% in 2023 to 56% in 2024.
- Guatemala: DENV-3 accounted for 83% of serotyped cases in 2024.
- Mexico: DENV-3 circulation surged from 6% in 2021 to 86% in 2024.
- Nicaragua: Historically, DENV-3 has been linked to higher severity.
- Peru: DENV-3 detected in multiple regions in 2024.
- Puerto Rico: Since 2023, DENV-3 has displaced DENV-1 as the predominant serotype.
Public Health Implications
- Increased susceptibility among populations due to prior lack of exposure to the serotype, potentially leading to more severe cases.
- DENV-3 is considered one of the most virulent serotypes, heightening the risk of hospitalization and severe complications.
- Health system overload if outbreaks are not adequately controlled.


